Celldex Therapeutics Inc
CLDX21.872USD
-0.318-1.43%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.45BCap. mercado
PérdidaP/E TTM
Más Datos de Celldex Therapeutics Inc Compañía
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Información de la empresa
Símbolo de cotizaciónCLDX
Nombre de la empresaCelldex Therapeutics Inc
Fecha de salida a bolsaMay 15, 1986
Director ejecutivoMr. Anthony S. Marucci
Número de empleados186
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 15
Dirección53 Frontage Road
CiudadHAMPTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal08827
Teléfono19084547120
Sitio Webhttps://celldex.com/
Símbolo de cotizaciónCLDX
Fecha de salida a bolsaMay 15, 1986
Director ejecutivoMr. Anthony S. Marucci
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
34.14K
+38.79%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Mr. Herbert J. (Herb) Conrad
Mr. Herbert J. (Herb) Conrad
Independent Director
Independent Director
2.56K
--
Mr. James J. (Jim) Marino
Mr. James J. (Jim) Marino
Independent Director
Independent Director
2.20K
--
Mr. Keith L. Brownlie, CPA
Mr. Keith L. Brownlie, CPA
Independent Director
Independent Director
666.00
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Anthony S. Marucci
Mr. Anthony S. Marucci
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.64K
+1.48%
Mr. Freddy A. Jimenez, Esq., J.D.
Mr. Freddy A. Jimenez, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
34.14K
+38.79%
Dr. Diane C. Young, M.D.
Dr. Diane C. Young, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
17.11K
-63.67%
Dr. Margo Heath-Chiozzi, M.D.
Dr. Margo Heath-Chiozzi, M.D.
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
13.74K
+2.70%
Ms. Elizabeth Crowley
Ms. Elizabeth Crowley
Senior Vice President, Chief Product Development Officer
Senior Vice President, Chief Product Development Officer
9.07K
--
Dr. Tibor Keler, Ph.D.
Dr. Tibor Keler, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.36K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Wellington Management Company, LLP
12.58%
Kynam Capital Management LP
9.79%
BlackRock Institutional Trust Company, N.A.
6.97%
Fidelity Management & Research Company LLC
5.85%
The Vanguard Group, Inc.
5.85%
Other
58.95%
Accionistas
Accionistas
Proporción
Wellington Management Company, LLP
12.58%
Kynam Capital Management LP
9.79%
BlackRock Institutional Trust Company, N.A.
6.97%
Fidelity Management & Research Company LLC
5.85%
The Vanguard Group, Inc.
5.85%
Other
58.95%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
45.68%
Hedge Fund
31.15%
Investment Advisor/Hedge Fund
29.65%
Research Firm
3.45%
Venture Capital
2.56%
Bank and Trust
0.33%
Pension Fund
0.31%
Individual Investor
0.27%
Insurance Company
0.04%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
419
75.39M
113.55%
-14.43M
2025Q1
437
75.31M
113.46%
-13.68M
2024Q4
437
75.05M
113.05%
-8.14M
2024Q3
429
73.28M
110.59%
-7.16M
2024Q2
432
71.48M
107.86%
-10.62M
2024Q1
419
71.32M
108.50%
+952.72K
2023Q4
406
62.72M
112.33%
-412.93K
2023Q3
403
52.10M
110.18%
-8.63M
2023Q2
410
51.84M
109.57%
-7.47M
2023Q1
419
51.38M
108.89%
-6.42M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Wellington Management Company, LLP
8.35M
12.58%
-621.68K
-6.93%
Mar 31, 2025
Kynam Capital Management LP
6.50M
9.79%
+1.44M
+28.35%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.62M
6.97%
-29.87K
-0.64%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.89M
5.85%
+441.18K
+12.80%
Mar 31, 2025
The Vanguard Group, Inc.
3.89M
5.85%
+16.44K
+0.42%
Mar 31, 2025
Eventide Asset Management, LLC
3.75M
5.66%
+1.53K
+0.04%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.35M
5.05%
-144.43K
-4.13%
Mar 31, 2025
Commodore Capital LP
3.35M
5.05%
+150.00K
+4.69%
Apr 03, 2025
Bellevue Asset Management AG
3.07M
4.63%
--
--
Mar 31, 2025
State Street Global Advisors (US)
2.81M
4.23%
-428.60K
-13.25%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ALPS Medical Breakthroughs ETF
0.91%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
SPDR S&P Biotech ETF
0.37%
Direxion Daily S&P Biotech Bull 3X Shares
0.21%
Nuveen ESG Small-Cap ETF
0.11%
Fidelity Fundamental Small-Mid Cap ETF
0.11%
T Rowe Price Small-Mid Cap ETF
0.1%
iShares Russell 2000 Value ETF
0.1%
Avantis US Small Cap Equity ETF
0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.07%
Ver más
ALPS Medical Breakthroughs ETF
Proporción0.91%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.9%
SPDR S&P Biotech ETF
Proporción0.37%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.21%
Nuveen ESG Small-Cap ETF
Proporción0.11%
Fidelity Fundamental Small-Mid Cap ETF
Proporción0.11%
T Rowe Price Small-Mid Cap ETF
Proporción0.1%
iShares Russell 2000 Value ETF
Proporción0.1%
Avantis US Small Cap Equity ETF
Proporción0.09%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporción0.07%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
